Introduction
Originally identified as an activator of type I interferon (IFN␣/␤) genes in response to viral infection, 1 the interferon regulatory factor-1 (IRF-1) transcription factor is now known to play a critical role in the normal physiologic activation of genes regulating differentiation, growth suppression, and apoptosis in hematopoietic and non-hematopoietic cell lineages. IRF-1 expression may be induced by many growth factors and cytokines, including IFN␥, TNF␣, IL-1, IL-3, IL-6, alltrans retinoic acid (ATRA), and LIF. [2] [3] [4] [5] However, like other key growth regulatory proteins, the regulation of IRF-1 expression is complex; IRF-1 mRNA is normally very low in abundance and IRF-1 proteins have a relatively short half-life. 6, 7 IRF-1 plays an important role in normal hematopoiesis; it is differentially expressed during myelopoiesis and has emerged as a critical regulator of B, T, and NK cell maturation. [8] [9] [10] [11] [12] Interestingly, the induction of IRF-1 in stromal cells is also essential for their production of certain cytokines (such as IL-12 and IL-15) that support the maturation of various hematopoietic lineages. [10] [11] [12] In addition to or as part of its role in hematopoiesis, IRF-1 induces growth suppression in both normal and virally infected cells. [13] [14] [15] [16] In association with p53, IRF-1 is required for the induction of the p21/WAF1/CIP1 cell cycle inhibitor. 17 IRF-1 is also required for induction of the PML growth suppressor, 18 and for the growth inhibitory effects of IFN␥. 15, 16 In addition to its role in growth suppression, IRF-1 plays a key role in both p53-dependent and p53-independent apoptosis, in part due to its regulation of Fas-antigen and interleukin-␤ converting enzyme (ICE) expression. [15] [16] [17] [19] [20] [21] Thus, altered expression of IRF-1 may contribute to the neoplastic phenotype by compromising differentiation, growth regulation, or apoptosis.
Over-expression of IRF-1 in transformed cells and tumor cell lines is sufficient to revert the neoplastic phenotype, leading to its more recent designation as a tumor suppressor gene. 7, 19, 22, 23 In contrast, IRF-2, a highly related transcription factor that recognizes the same DNA sequence motif as IRF-1, effectively competes with IRF-1 for binding to the promoter element of target genes resulting in repression of the same set of genes induced by IRF-1. 24, 25 As predicted, overexpression of IRF-2 in fibroblasts is oncogenic. 26 IRF-1 is a transcriptional activator of IRF-2, but does not directly regulate its own expression. 24 Maintenance of a normal non-neoplastic phenotype may thus depend upon the relative balance of IRF-1 and IRF-2. 7, 25 In 1993, we first mapped IRF-1 to chromosome 5q31.1, 27 a region frequently deleted in acute myeloid leukemias (AML; particularly secondary and therapy-induced AML and AML arising in the elderly population) and myelodysplasia (MDS). [27] [28] [29] [30] [31] [32] [33] We demonstrated a loss of at least one IRF-1 allele in each of 13 AML/MDS patients with chromosome 5q31.1 anomalies. In addition, six samples had subpopulations of cells (у10%) with loss of both IRF-1 alleles detected by fluorescence in situ hybridization (FISH) and one sample had a deletion of one IRF-1 allele accompanied by a non-functional rearrangement of the residual allele. 27 No detectable mutations or rearrangements of the DNA coding region were detected by ribonuclease protection assays or direct sequencing in the remaining cases (C Willman, unpublished data). More recent cytogenetic and molecular mapping studies have revealed both the complexity and heterogeneity of chromosome 5q deletions in AML/MDS, suggesting that there may be more than one and perhaps as many as three distinct regions of minimal overlapping deletion in patients with different forms of leukemia and MDS. [27] [28] [29] [30] [31] [32] [33] As no single 'classic' tumor suppressor gene has yet been identified in any of these regions, the possibility remains that the haploinsufficiency that results from deletion of various large regions of chromosome 5q promotes or contributes to establishing the leukemic phenotype.
As IRF-1 is in fact deleted in the majority of AML/MDS cases with −5/del(5)(q31), we have continued to explore whether hemizygous loss of IRF-1, resulting in haploinsufficiency, could contribute to the leukemic phenotype. While mutation of non-coding regions, microdeletion, or promoter methylation of the residual IRF-1 allele could result in functional inactivation, we have focused on the role of 'exon-skipping'. Exon-skipping occurs when there is a failure of the splicing machinery to correctly identify one or more exon boundaries within a primary RNA transcript, leading to the inappropriate exclusion of coding exons in a processed mRNA. 34 Harada and colleagues 35 first demonstrated that the transcription and splicing of the primary human IRF-1 transcript is frequently accompanied by exon skipping, resulting in two partial IRF-1 RNAs: IRF-1⌬2 lacking exon 2 (containing the translation initiation site) and IRF-1⌬2,3 lacking both exons 2 and 3 (containing the DNA binding domain). Because these exonskipped transcripts both lack the authentic translation initiation site, exon-skipping of the IRF-1 transcript may result in a significant reduction in the amount of translatable fulllength mRNA, leading to functional inactivation. Unlike the examples of p53 and WT1, where exon-skipping downstream of the translation initiation site leads to the production of truncated proteins that may act as 'dominant negative' mutants, there is no evidence that the truncated IRF-1 transcripts are translated in vivo. [35] [36] [37] [38] To test the hypothesis that functional inactivation of IRF-1 could occur in AML and MDS as a result of accelerated exonskipping, particularly in those cases with −5/del(5)(q31) that had already deleted one IRF-1 allele, we developed quantitative competitive RT-PCR assays to measure levels of full length IRF-1, IRF-1⌬2, and IRF-1⌬2,3 transcripts in normal and leukemic hematopoietic cells and correlated exon-skipping with IRF-1 protein expression. In this study, we find that accelerated exon-skipping and a loss of IRF-1 protein expression occurs in a subset of AML/MDS cases with −5/del(5)(q31) and unexpectedly in all cases of acute promyelocytic leukemia with t(15;17).
Materials and methods

Patient samples
Fourteen AML patient samples with cytogenetically defined deletions or translocations involving band 5q31.1 and high blast percentages (most Ͼ95% and none Ͻ70%) were identified in the Southwest Oncology Group (SWOG) Repository at UNM or through UNM cytogenetic records. Only high blast count cases were selected so that isolated RNA and proteins reflected IRF-1 expression in enriched leukemic cells and not residual cells potentially contained within a specimen. As controls, additional AML samples with high (Ͼ90%) blast counts and defined cytogenetic abnormalities not involving 5q31.1 were identified: t(15,17) (n = 11); inv(16) (n = 7) and t(8,21) (n = 7). Buffy-coat cells (PBL) from three normal donors were obtained from United Blood Services (Albuquerque, NM, USA) and surplus material from normal bone marrow samples (n = 3) was obtained from UNMH. All samples had been previously cryopreserved and stored at −135°C prior to use.
Cytogenetic analysis
Cytogenetic studies on pretreatment bone marrow or unstimulated blood samples were performed using standard G-banding with trypsin-Giemsa or trypsin-Wright's staining in SWOG-approved Cytogenetic Laboratories. Karyotypes were interpreted using International System for Cytogenetic nomenclature (ISCN) criteria (1995) . 39 Karyotypes were considered normal diploid if no clonal abnormalities were detected in a minimum of 20 metaphases examined and if two independent cell-processing methods were used. Each karyotype was independently reviewed by at least three members of the SWOG Cytogenetics Committee.
Fluorescence in situ hybridization (FISH)
Cytospin preparations of previously cryopreserved interphase cells were fixed in Carnoy's fixative (75% v/v methanol, 25% v/v acetic acid) prior to hybridization. FISH with chemically modified DNA probes specific for the IRF-1 gene (biotinylated RMC05p007; Resource for Molecular Cytogenetics (RMC), UCSF, San Francisco, CA, USA) and for a locus on 5p15.2 (digoxygenin-labelled RMC-5p002; RMC) was performed to distinguish normal diploid, monosomy 5 and 5q− or 5p− cells as described by Pinkel et al. 40, 41 Hybridization domains were quantified using fluorescence microscopy. Green and red fluorochromes were visualized simultaneously using a Chroma Technology multiband emission filter (81P101) and beam splitter (81P100) with a dual band excitation filter (81P102). At least 200 cells were scored on each slide. Cells with disrupted nuclear membranes were excluded from analysis. Hybridization domains were considered to represent two chromosomes if the fluorescent hybridization signals were separate and non-overlapping. Cells were considered to be monosomic for IRF-1 if the cell showed one IRF-linked hybridization domain and two 5p domains. Cells with one IRF domain and one 5p domain were considered to be −5. The hybridization efficiency of digoxygenin-labeled RMC05p002 and biotin-RMC05p007 ranged between 80-91%, as determined by scoring the number of hybridization domains in interphase cells from three non-leukemic blood specimens and from two leukemic marrow specimens without cytogenetic evidence of chromosome 5 anomalies. The hybridization efficiency for interphase and metaphase FISH were comparable. Hybridization data from three normal specimens of blood or bone marrow (600 cells total) were pooled to determine the percent of aneusomic domains in normal cells using the 5p and 5q DNA probes. A 95% upper limit for the percent abnormal cells based on scoring 200 cells was determined as described by Blyth. 42 This upper limit was then used to determine whether a tumor sample with 200 cells scored had significantly more abnormal cells than would be expected for normal samples. 
Oligonucleotide primers and internal standard RNA
Quantitative competitive RT-PCR assay
Total cellular RNA was isolated by guanidinium isothiocyanate cell lysis, ultracentrifugation through a cesium cushion and guanidine-HCl solubilization followed by serial acetic acid/ethanol and potassium acetate/ethanol precipitations according to the method of Chirgwin et al. 44 RNAs were quantitated by absorbance at 260 and RNA integrity was confirmed by visualization of ethidium bromide stained ribosomal RNA bands on an agarose gel.
Reverse transcriptions of IRF-1 mRNAs were performed essentially as described 35 with the exception of the addition of internal standard cRNA. For each sample, five RT reactions were prepared each containing 500 ng of sample RNA. RNA and RT primer mixtures were denatured at 95°C for 2 min, chilled on ice, then allowed to anneal at 37°C for 30 min. After annealing, reactions were brought to 20 l with RT master mix, bringing the final reaction conditions to 0.5 g sample RNA + internal standard RNA, 1 pmol RT primer, 20 units RNAsin, 100 units M-MLV RT, 50 mM Tris, 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol (DTT), 10 nM each of dATP, dCTP, dTTP and dGTP. Reactions were incubated at 37°C for 60 min. The RT enzyme was inactivated by incubation at 95°C for 5 min. Prior to PCR reactions, 40 l of DEPC-H 2 O were added to each reaction to dilute the DTT.
PCR primers were end-labeled to high specific activity using T4 polynucleotide kinase (New England Biolabs). For each sample, a 10 l reaction consisted of 3 l RT in a reaction mixture containing 10 mM Tris-HCl, pH = 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 200 nM each of dATP, dCTP, dGTP and dTTP, 20 pM IRF-1 5Ј Primer, 20 pM IRF-1 3Ј Primer and 0.25 units of Taq polymerase (AmpliTaq; Perkin Elmer, Branchburg, NJ, USA). Reactions were performed in a Perkin Elmer 9600 thermocycler and consisted of a 2 min 95°C incubation to remove secondary structure, followed by 24 cycles of 30 s at 95°C, 30 s at 55°C and 60 s at 72°C. A 10-min elongation step at 72°C followed the amplification cycles. Five l of each PCR product were electrophoresed in a 5% acrylamide/1.0 × TBE gel and dried gels were analyzed on a PhosphorImager using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA).
Quantitation of pre-amplification levels of the IRF-1 mRNAs (eIRF-1) was accomplished by determination of gel band densities corrected for background and for relative intensity of internal standard RNAs (IS). The level of endogenous IRF-1 mRNAs was calculated for each concentration of internal standard RNA using the equation:
This calculation provides a result that is co-linear with band densities, yet more conservative because effects of competition between the sample and standard RNAs are reflected in the error bars for each of the sample mRNAs. For each patient RNA, multiple tubes containing the same amount of patient RNA were analyzed to assess error associated with pipetting or enzyme activity/tube. The data are presented as the average calculated eIRF−1 +/− s.e.m. for each sample as molecules per 0.5 g RNA.
Cloning and sequencing
IRF-1 RT-PCR products were agarose gel purified and cloned into the pCR-Script SK(+) plasmid using the pCR-Script Amp SK(+) cloning kit (Stratagene, La Jolla, CA, USA). The fulllength product was cloned independently from RNA isolated from three patient samples and normal bone marrow cells. The IRF-1⌬2,3 exon-skipped transcript was cloned independently from RNA isolated from a separate patient sample, and from two of the three leukemia samples from which full-length sequence was obtained. All cloned products were sequenced by the dideoxynucleotide chain-termination method (United States Biochemical, Cleveland, OH, USA) using T7 and T3 sequencing primers. Cloned PCR products were sequenced in both directions and sequences were read manually by at least two readers.
Short-term cell culture
Cryopreserved cells were rapidly defrosted, viable cells counted using trypan blue dye exclusion, and plated in duplicate at a density of 0.5-1.0 × 10 6 viable cells/ml in media (RPMI, 15% FCS) and allowed to settle for 2-16 h prior to addition of induction agents. IFN␥ (R&D Systems, Minneapolis, MN, USA) was added to one set of cultures at 500 U/ml for 6 h at 37°C in the presence of 5% CO 2 ; the duplicate cultures were incubated under the same conditions without interferon. The t(15;17) samples were incubated with IFN␥ (500 IU/ml), ATRA (100 nM), or without additional agents. The NB4 acute promyelocytic leukemia (APL) cell line, 45 a kind gift from M Lanotte, was used as a positive control in the t(15;17) experiment. Continuously growing NB4 cells, maintained at 0.2-1 × 10 6 cells/ml were plated at a density of 0.5 × 10 6 cells/ml and allowed to settle for 2 h prior to the addition of induction agents.
Western blot
For unstimulated cells, cryopreserved samples were defrosted, viable cells counted using trypan blue dye exclusion, and lysed with RIPA lysis buffer (PBS with 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) containing 10 g/ml protease inhibitors (phenylmethylsulfonylfluoride, leupeptin, and aprotinin), 5 mM sodium fluoride, and 1 mM sodium orthovanadate at 20 l lysis buffer per 10 6 viable cells. For cells in short-term culture with inducing agents, cells were harvested by centrifugation, washed in PBS and viable cells counted using trypan blue dye exclusion, and lysed with RIPA lysis buffer containing 10 g/ml protease inhibitors, 5 mM sodium fluoride, and 1 mM sodium orthovanadate at 20 l lysis buffer per 10 6 viable cells. For all blots, lysate supernatants from 1.25 × 10 6 cells were combined with an equal volume of sample buffer (8 M urea, 5% SDS, 1% ␤-mercaptoethanol) and resolved by urea/SDS-PAGE (4 M urea; 11.5% acrylamide, 1% SDS). Proteins were transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA) and probed with various antibodies: affinity purified rabbit polyclonal antibodies directed against the C-terminal region of IRF-1 or IRF-2 (Santa Cruz Biotech, Santa Cruz, CA, USA), a murine monoclonal antibody directed against the human Bcl-2 protein (Santa Cruz Biotech), or a murine monoclonal antibody directed against ␤-actin (Sigma Immunochemicals, St Louis, MO, USA). Secondary antibodies provided as horseradish peroxidase conjugates included goat-anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA) and goat-antimouse IgG2 (Amresco, Solon, OH, USA). Bound antibody was detected via incubation in SuperSignal CL-HRP Substrate System reagents (Pierce, Rockville, IL, USA) and subsequent exposure to Biomax-MR film (Eastman-Kodak, Rochester, NY, USA).
Results
Patient selection and sample characterization
In order to determine whether AML cases with −5 or del(5)(q31) had accelerated exon-skipping and a functional loss of IRF-1 expression from the retained IRF-1 allele, we selected a series of previously cryopreserved, cytogenetically characterized AML samples with one or two IRF-1 alleles for study. A series of myeloid cell lines (U937, HL60, NB4) and normal bone marrow and peripheral blood samples were selected as controls. As an additional criterion, we selected only leukemia samples with high blast cell counts so that normal residual cells in the specimen did not dilute RNA or protein preparations for analysis. Using these criteria, we selected pre-treatment samples from 14 AML patients with chromosomal deletions or translocations specifically involving band 5q31.1 or with monosomy 5, seven samples with cytogenetically confirmed t(8;21), seven with cytogenetically confirmed inv (16) , and 11 cases of APL with cytogenetically confirmed t(15;17) or molecularly confirmed PML-RAR␣ fusion transcripts (Table 1) .
In rare cases, an IRF-1 allele may be retained in AML cases with minimal deletions involving band 5q31, 29, 46 or in balanced translocations involving band 5q31.1. Therefore, as described in materials and methods, we performed fluorescence in situ hybridization (FISH) analysis in interphase on thawed previously cryopreserved leukemic cell suspensions from all AML cases with −5/del(5q)(31) in order to confirm allelic loss of IRF-1 (Figure 1) . This quantitative FISH screen performed to validate our selected samples resulted in the exclusion of sample 12 (Table 1 ) from our study group; this sample, which contained a t(3;5)(q21;q31), clearly retained both IRF-1 alleles. FISH analysis confirmed that all other AML samples with −5/del(5q) had a single IRF-1 allele (Figure 1 ; 95% confidence interval). No cytogenetic or molecular cytogenetic changes involving chromosome 5q were seen in the other leukemia samples evaluated (Table 1 and Figure 1) . Of other cytogenetic abnormalities in the AML samples containing a −5/del(5q), monosomy 7 was the most frequent, occurring in seven of the 14 cases initially selected for analysis (Table 1) .
Cloning and sequencing of IRF-1 exon-skipped transcripts
To further confirm the identity and determine the sequence at various exon junctions in the full length and exon-skipped IRF-1 RNAs, we independently cloned and sequenced the fulllength IRF-1 and IRF-1⌬2,3 RT-PCR products (using primers detailed in materials and methods) obtained from normal bone marrow and four AML patient RNA samples. Multiple attempts to clone the IRF-1⌬2 transcript were unsuccessful. Although it was originally hypothesized that exon-skipping during IRF-1 transcription and splicing might result from a non-canonical intron 1-exon 2 boundary, 35 our sequence analysis of full-length and exon-skipped IRF-1⌬2,3 transcripts indicates that the published intron 1/exon 2 boundary in the genomic IRF-1 sequence (Humifnrfla, GenBank Accession No. L05072) was incorrectly identified. As illustrated in Figure 2a , our sequence data from the exon 1/exon 2 and the exon 1/exon 4 junctions (recently deposited in GenBank: Accession No. AF082503) indicate that intron 1 should be shifted by four bases such that exon 1 is four bases longer and exon 2 is four bases shorter than previously reported. 47 With this change, the IRF-1 intron/exon 2 splice junction conforms to expected motifs, with the intron containing a polypyrimidine tract followed by a terminal intronic AG (Figure 2b) . Therefore, in contrast to speculation by others, this canonical splice junction sequence is unlikely to contribute to exonskipping of the IRF-1 primary transcript, and the basis for exon-skipping during IRF-1 transcription and splicing remains undetermined.
Development of quantitative competitive RT-PCR assay for IRF-1 full-length and exon-skipped transcripts
The relative and absolute levels of full-length and exonskipped IRF-1⌬2 and IRF-1⌬2,3 RNAs were determined in our series of patient samples and controls using a highly sensitive quantitative competitive RT-PCR assay (see Methods). This assay was performed by preparing a series of samples from each patient sample or control that incorporated increasing known quantities of an internal reference IRF-1 mRNA into each RNA sample prior to the PCR reaction. PCR amplification was performed in the exponential range and amplification of the samples and internal reference standard was linear over the range of concentrations assessed (data not shown). Figure 3 provides autoradiographs from four representative individual samples to illustrate the reproducible amplification of the 379 bp full-length IRF-1, the 340 bp internal reference standard IRF-1 RNA, and the exon-skipped 287 bp IRF-1⌬2 and 187 bp IRF-1⌬2,3 transcripts from multiple reactions. Using this assay, some leukemic samples were found to have relatively less full-length IRF-1 mRNA and more exonskipped IRF-1 mRNA than others (see following discussion; [16] the range of variation is illustrated by samples shown in Figure 3 ). However, exon-skipped IRF-1 RNAs were clearly evident, to varying degrees, in all normal bone marrow and peripheral blood samples analyzed; thus, exon-skipping is not unique to the leukemic phenotype. The relative and absolute levels of the full-length and exonskipped IRF-1 RNAs determined by the quantitative competitive RT-PCR assay for each AML sample, normal controls, and three myeloid cell lines are provided in Figure 4 . Using this assay, the number of full-length IRF-1 molecules per 500 ng RNA ranged from 9.33 × 10 5 molecules in the U937 cell line to 7.4 × 10 6 molecules in sample 11 (Table 1) , an AML sample with del(5q). The quantitative mean of full-length IRF-1 molecules in these samples was 3.05 (+/− 1.32) × 10 6 molecules per 500 ng RNA and the median was 2.72 × 10 6 molecules per 500 ng RNA. Based upon the number of cells that we utilized for RNA isolation and the yield of RNA obtained, these quantitative values can be converted to a per cell IRF-1 transcript copy number. Our results indicate that primary leukemia cells contain on average only three copies of full-length Frequency of del 5q31 (IRF-1 locus) in leukemic samples. The frequency of cells with del 5q31 was quantified using fluorescence microscopy after performing FISH on previously cryopreserved interphase cells. The mean and upper and lower 95% confidence intervals for the frequency of cells with one hybridization domain are shown for normal peripheral blood controls, 13 leukemic samples with cytogenetic anomalies of 5q, and two leukemic samples without cytogenetic anomalies of 5q. The dashed line indicates the 95% confidence limit for hemizygous deletion of the IRF-1 locus.
IRF-1 mRNA and confirm that, like other tumor-suppressor and growth-regulatory genes, IRF-1 mRNA is very low in abundance in most normal and leukemic samples.
Taking the low levels of transcript into account, we considered samples with less than 1.5 × 10 6 full-length IRF-1 mRNA molecules to have significantly decreased levels of IRF-1 expression. This designation includes only primary samples at or below the 20th percentile of full-length IRF-1 expression of the samples analyzed. Exon-skipping was considered 'accelerated' when the full-length IRF-1 transcript constituted less than 50% of the total quantitative IRF-1 transcripts. Using these criteria, 2/13 AML samples with −5 or del(5q) (Figure 4 , pts 4 and 10) had low levels of full-length IRF-1 mRNA transcripts. One sample with low full-length IRF-1 mRNA also had accelerated exon-skipping (Figure 4, pt 10) . A second sample with del(5q) and accelerated exon-skipping had Ͻ2 × 10 6 molecules of full-length IRF-1 mRNA ( Figure 4 , pt 2; this sample is also illustrated in Figure 3) .
Unexpectedly, all of the APL samples were surprisingly different from other primary AML samples and cell lines despite the retention of both IRF-1 alleles in these samples. Four of the five APL samples shown in Figure 4 (samples 15, 17, 18 and 19) contained low levels of full-length IRF-1 mRNA transcripts (estimated at less than one to two copies per cell) and three of five APL patient samples (Figure 4, pts 15, 16 and 17 ) demonstrated accelerated exon-skipping (Figure 4) . Unlike the primary APL patient samples, however, the established NB4 APL cell line, which is a popular model for studies of APL, had significant levels of expression of full-length IRF-1 mRNA transcripts and no significant evidence of exon-skipping of the IRF-1 transcript. In this regard, it is interesting that the two other myeloid cell lines examined had extremely low to nearly undetectable levels of expression of full-length IRF-1 mRNA transcripts and essentially no exon-skipping.
All of the normal PBL and BM samples and all of the AML samples with inv(16) had levels of full-length IRF-1 mRNA transcripts in the range of 2-4 × 10 6 molecules per 0.5 g RNA. In contrast, all of the AML samples with t(8;21) contained higher levels of full-length IRF-1 mRNA transcripts (at 4-6 × 10 6 molecules per 0.5 g RNA; estimated at greater than or equal to four to six copies per cell). The quantitative amount of the full-length IRF-1 mRNA transcript constituted Ͼ65% of the total IRF-1 transcript for all of the inv(16), t(8;21) and normal PBL/BM samples. 
Determination of IRF-1 protein expression in AML samples
Western blotting was used to correlate the levels of exon-skipping and the quantitative amounts of full-length IRF-1 mRNA detected in each sample with the amount of IRF-1 protein produced in each sample. Protein lysates from samples and controls were normalized for the number of viable cells at the time of lysis to control for the variability of cell size across the different leukemic and normal cell populations evaluated. Figure 5 demonstrates the levels of constitutive expression of the IRF-1 protein, its highly homologous competitive inhibitor IRF-2, and an internal control (␤-actin) in cells from eight AML samples with −5 or del(5q), three AML samples with inv (16) , and a normal peripheral blood sample. Very low levels of IRF-1 proteins were detected in five of eight AML samples with −5/del(5q) and in two of three AML samples with inv(16) (Figure 5a) ; IRF-1 protein was undetectable in normal unin-
Figure 4
Absolute and relative amounts of IRF-1 transcripts in AML. IRF-1 transcript levels for each sample are presented illustrating the relative and absolute transcript abundance. The asterisk indicates pt 12, the sample with a t(3;5) which retained both IRF-1 alleles by FISH analysis. PBL 2 is a representative normal peripheral blood sample and BM 1 is a representative normal bone marrow sample.
duced peripheral blood. Samples with detectable IRF-1 protein had between 2-6 × 10 6 molecules of full-length IRF-1 transcript per 500 ng total RNA, and the full-length transcript for these samples constituted Ͼ65% of the total IRF-1 mRNA. These data are in accordance with other reports that constitutive levels of IRF-1 proteins are low in most samples. 6 A parallel blot was prepared and probed for IRF-2 protein levels, which is generally considered a constitutively expressed protein that can be further induced by IRF-1. Variable levels of IRF-2 protein could be detected in all samples with the exception of AML patient sample 4, which lacked detectable IRF-1 protein (Figure 5a, lane 3) ; very low levels of IRF-2 were also seen in AML sample 2 with del(5q) and in the normal peripheral blood sample (Figure 5a, lanes 1 and 12) . Re-probing of the IRF-1 blot with antibodies to ␤-actin confirmed the presence of protein in all samples (Figure 5a ).
Induction of IRF-1 protein in AML
Because IRF-1 is a low abundance, tightly regulated, inducible transcription factor, we wanted to determine whether IRF-1 proteins could be induced in those samples that contained low levels of full-length IRF-1 transcript, had significant exonskipping, or had low levels of IRF-1 proteins. We used a shortterm culture assay to evaluate the ability of IFN␥ to induce IRF-1 protein and lysates from both unstimulated and stimulated cells exposed to IFN␥ for 6 h. This time interval (6 h) was determined after stimulating two AML patient samples expanded in culture and exposed to various doses of IFN␥ or ATRA, then harvested at 2, 4, 6, or 24 h. For both AML samples, maximal IRF-1 induction was observed at 6 h at 100-1000 U/ml IFN␥ (data not shown). Therefore, primary AML samples were cultured for 6 h, then analyzed by Western blotting (Figure 5b ). Despite the very low to undetectable levels of expression of IRF-1 protein in most AML samples with −5 or del(5q) or in normal peripheral blood, exposure of these samples to IFN␥ significantly increased the levels of IRF-1 proteins in each sample (Figure 5b , patient samples 1, 6, 14, 5, 11 and PBL). Interestingly, in repeated experiments, IFN␥ was not capable of significantly inducing expression of IRF-1 proteins in both AML samples with −5/del(5q) that had demonstrated accelerated exon-skipping and low levels of full-length IRF-1 mRNA ( Figure 5b , pt 10; and in patient sample 2 (data not shown)). Similarly, in patient sample 4, which had very low levels of full-length IRF-1 mRNA (Figure 4) , IFN␥ exposure resulted in only barely detectable levels of IRF-1 protein (Figure 5b) . In contrast to these AML samples with −5 or loss of one IRF-1 allele, all AML samples with inv(16) or t(8;21) demonstrated a significant induction of IRF-1 protein with IFN␥ exposure compared to the lower levels expressed in unstimulated cells (Figure 5b, second panel) .
Lack of induction of IRF-1 proteins in primary APL samples
Our observation that all APL samples were characterized by very low levels of expression of full-length IRF-1 mRNA transcripts and most exhibited significant degrees of exon-skipping (Figure 4 ) was unexpected. Examination of these primary APL samples for IRF-1 protein expression revealed no detectable IRF-1 protein in any sample examined (Figure 6a, lanes 2-6) . In contrast to these primary samples, low levels of IRF-1 protein could be detected in unstimulated NB4 cells (Figure 6a Given that IFN␥ failed to induce IRF-1 expression in primary APL samples, we examined the ability of other clinically relevant differentiation-inducing or apoptosis-inducing agents used in the therapy of APL to induce IRF-1 gene and protein expression. Additionally, all-trans retinoic acid (ATRA) has been reported to induce IRF-1 expression in NB4 cells through a retinoic acid-responsive element in the IRF-1 promoter. 4 Surprisingly, repeated experiments with IFN␥ and ATRA failed to induce any detectable IRF-1 protein in three of four APL samples initially evaluated, despite significant induction of IRF-1 protein levels in the established NB4 APL cell line (data not shown). One APL sample (Table 1; pt sample 19) showed a very weak induction with IFN␥ but no induction with ATRA (data not shown). Figure 6b provides the results from a second set of experiments performed on an additional six primary APL patient samples (Figure 6b, lanes 1-6) , as well as the U937 (Figure 6b, lane 7) and NB4 cell lines (Figure 6b, lane 8) . Each of these samples or cell lines were stimulated in short-term culture with ATRA or IFN␥. Strikingly, neither ATRA nor IFN␥ was capable of inducing IRF-1 proteins in any of the primary APL samples (Figure 6b, lanes 1-6) . In contrast, IRF-1 protein was induced to significant levels in NB4 cells (Figure 6b , lane 8) and to a much lower degree in U937 cells (Figure 6b , lane 7) in response to both ATRA and IFN␥. These experiments highlight clear differences in responsiveness between primary APL patient samples and the established NB4 cell line, pointing to the limitations in the use of transformed leukemic cells for the study of disease and therapeutic responsiveness. In summary and in contrast to NB4 cells, all 11 primary APL samples examined in this study had either low levels of fulllength IRF-1 transcripts or accelerated exon-skipping, and all failed to demonstrated a significant induction of IRF-1 protein in response to IRF-1 inducing agents (ATRA and IFN␥). These data implicate a loss of IRF-1 function specifically in APL. Failure of IRF-1 induction, which promotes growth suppression and apoptosis, may lead to persistence of the leukemic clone despite exposure to inducing agents.
Discussion and conclusions
To test the hypothesis that exon-skipping of the IRF-1 transcript is a mechanism of functional inactivation of the IRF-1 tumor suppressor gene in human myeloid leukemia, we specifically addressed whether: (1) exon-skipping occurs preferentially in leukemic vs normal hematopoietic cells; (2) exonskipping is more prominent in leukemia samples with one vs two IRF-1 alleles; and (3) accelerated exon-skipping results in a concomitant decrease in either the absolute amount of fulllength transcript or in the amount of constitutive or inducible protein. We have determined that exon-skipping occurs in both normal and leukemic cells; however, why exon-skipping occurs preferentially during transcription and splicing of IRF-1 and whether this phenomenon might be physiologically regulated during normal hematopoiesis remains to be determined. Cloning and sequence analysis of both full-length and IRF-1 exon-skipped transcripts revealed the existence of canonical splice junction sequences at the exon 1/intron 1/exon 2 boundaries; thus we determined that prior explanations for accelerated exon-skipping based upon the presence of non-canonical splice junction sequences were incorrect. Using highly sensitive quantitative competitive RT-PCR assays, we further determined that accelerated exon-skipping occurs in a subset of the −5/del(5q) samples with loss of one IRF-1 allele, and unexpectedly, in the majority of cases of APL. In these leukemia samples that demonstrated accelerated exon-skipping or exceedingly low levels of full-length IRF-1 transcripts, IRF-1 protein could not be detected and could not be induced with either IFN␥ or ATRA.
Exon-skipping as a means of inactivation of gene expression has been demonstrated to occur in both the p53 and Wilm's tumor (WT1) suppressor genes. [36] [37] [38] In these examples, exonskipping occurs distal to the translation initiation site; the proteins translated from these exon-skipped transcripts are C-terminally truncated and may function as oncogenic 'dominantnegative' mutants of the wild-type proteins. In contrast, both IRF-1 exon-skipped splice products (IRF-1⌬2 and IRF-1⌬2,3) lack the major translation initiation start site in exon two and delete all or part of the 5-tryptophan motif, which characterizes the DNA binding region of IRF family member proteins. 48 Thus, a dominant-negative mechanism is unlikely in this instance; however, accelerated exon-skipping (particularly from cells that have retained only one IRF-1 allele) can clearly result in insufficient production of the fulllength transcript and a functional loss of IRF-1.
Three of 13 AML samples with −5 or anomalies of chromosome 5q31 had accelerated exon-skipping and/or extremely low levels of full-length IRF-1 transcripts; interestingly, IRF-1 proteins were not expressed and could not be significantly induced in these samples with IFN␥. While the remaining cases of AML with loss of one IRF-1 allele had variable levels of full-length and exon-skipped transcripts, our data indicate that loss of one IRF-1 allele alone does not necessarily result in accelerated exon-skipping and functional inactivation of the residual allele. What distinguishes the three AML cases with only one IRF-1 allele and an apparent loss of IRF-1 function from the remaining AML cases with −5 or del (5q) is not yet clear. Furthermore, why these three cases would fail to induce IRF-1 proteins in response to IFN␥ is unknown and currently under investigation.
An unexpected finding in our study was the apparent complete lack of expression of IRF-1 proteins in all primary cases of APL evaluated. Interestingly, APL cases also frequently demonstrated accelerated exon-skipping of the IRF-1 transcript. Furthermore, and in contrast to the established NB4 APL cell line, IRF-1 proteins could not be induced in these primary APL samples by either IFN␥ or ATRA. Our use of the NB4 cells as a positive control in the IRF-1 protein induction studies stems from previously demonstrated evidence that IRF-1 is induced by ATRA in these cells. 4 Thus, the demonstrated induction of IRF-1 in the NB4 cells serves as a control for the activity of agents used as inducers of IRF-1 in the short-term culture assay.
The results in the primary APL cells are surprising given that the IRF-1 promoter has a retinoic acid response element and ATRA has been shown to induce IRF-1 in transformed NB4 cells. These findings further highlight the importance of studying primary AML samples in addition to AML/APL cells lines that have been transformed and adapted to survive in vitro. It is possible that such adaptations may contribute to the observed IRF-1 induction in the NB4 cells. Some key differences between NB4 cells and the primary patient samples used here include: (1) the NB4 cell have cytogenetic abnormalities in addition to the t(15;17) that is characteristic of APL; 45 (2) NB4 cells grow continuously in culture, and are therefore likely to have a much higher percentage of actively cycling cells than the previously cryopreserved patient samples. (3) In contrast to the presentation phase patient samples analyzed the NB4 cell line was derived from leukemic cells harvested during a post-chemotherapeutic relapse. However, we readily observed induction of IRF-1 protein in several other primary leukemia samples treated identically to the APL samples; in addition, the other cell lines evaluated at the transcriptional (HL60, U937) and protein (U937) level failed to demonstrate increased levels of IRF-1 transcripts or protein as compared to non-APL primary patient samples.
We speculate that the PML/RAR␣ fusion product resulting from the APL-associated t(15;17) may directly interfere with the retinoid pathway of IRF-1 induction, and potentially block access to other cis activation sites on the IRF-1 gene promoter. Current models of APL pathogenesis invoke a constitutive association of the PML/RAR␣ fusion protein with a histone deacetylase complex (HDAC) and nuclear co-repressor (NCoR), leading to transcriptional repression of target genes. 49 IRF-1, with its RAR-E promoter element, may be a target for repression via this model. However, although ATRA has been reported to cause dissociation of this complex from some promoters in vitro, we failed to observe the induction of IRF-1 with ATRA (or IFN␥) in short-term culture of primary APL cells. A failure of ATRA to relieve the transcriptional repression of IRF-1 by PML-RAR␣ could result in a failure to completely activate growth suppression and apoptosis pathways, leading to persistence of a leukemic clone that is resistant to apoptosis in vivo.
